Literature DB >> 7632944

The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria.

S G Shaughnessy1, E Young, P Deschamps, J Hirsh.   

Abstract

Osteoporosis is a well-recognized complication of long-term heparin use. However, the mechanisms by which heparin can influence bone metabolism are unclear. We report here that unfractionated heparin stimulates the process of bone resorption and that the low molecular weight heparins (LMWHs), enoxaparin, fragmin, logiparin, and ardeparin produce significantly less calcium loss than unfractionated heparin. To assess calcium loss from bone, we quantified the release of 45Ca into the culture medium of fetal rat calvaria. 45Ca release was increased in a dose-dependent manner by the addition of either unfractionated heparin or the LMWHs; but more than 50-fold higher LMWH concentrations were required to obtain an equivalent effect to unfractionated heparin. Thus, at concentration > or = 2 micrograms/mL (0.35 anti-Xa units/mL), unfractionated heparin stimulated 45Ca release 1.53 +/- 0.06 fold. 45Ca release was increased to a similar extent by the addition of either 10(-7) mol/L parathyroid hormone (PTH) or 10(-6) mol/L 1,25 dihydroxyvitamin D3 (1,25 Vit D3). In contrast to unfractionated heparin, LMWH concentrations > or = 100 micrograms/mL (> or = 14.0 anti-Xa units/mL) were required before maximum isotope release was observed. At concentrations well above therapeutic levels, the LMWHs stimulated 45Ca release by only 1.25 /+- 0.01-fold. Heparins with high and low antithrombin III affinities stimulated 45Ca release equally well. Both size and sulfation were found to be major determinants of heparin's ability to promote isotope release. Thus, the ability of defined heparin fragments to stimulate 45Ca release correlated with their molecular weight, and after N-desulfation the ability of heparin to induce isotope release was greatly diminished. Dermatan sulfate had no effect on 45Ca release. We conclude that size and sulfation are major determinants of heparin's ability to promote bone resorption and that the risk of heparin-induced osteoporosis may be reduced by the use of LMWH preparations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7632944

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

Review 1.  New thrombolytics, anticoagulants, and platelet antagonists: the future of clinical practice.

Authors:  R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 4.  New data on the pharmacology of heparin and low molecular weight heparins.

Authors:  M M Samama; L Bara; I Gouin-Thibault
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 5.  Current and future management of pediatric venous thromboembolism.

Authors:  Bryce A Kerlin
Journal:  Am J Hematol       Date:  2012-02-24       Impact factor: 10.047

6.  Histopathologic effects of a low molecular weight heparin on bone healing in rats: a promising adjuvant in dacryocystorhinostomy.

Authors:  Mehmet Numan Alp; Ozdamar Fuad Oken; Mustafa Fevzi Sargon; Ahmet Ucaner
Journal:  Int J Ophthalmol       Date:  2016-06-18       Impact factor: 1.779

7.  Bone marrow-derived heparan sulfate potentiates the osteogenic activity of bone morphogenetic protein-2 (BMP-2).

Authors:  Diah S Bramono; Sadasivam Murali; Bina Rai; Ling Ling; Wei Theng Poh; Zophia Xuehui Lim; Gary S Stein; Victor Nurcombe; Andre J van Wijnen; Simon M Cool
Journal:  Bone       Date:  2011-12-28       Impact factor: 4.398

8.  Inhibition of osteolytic bone metastasis by unfractionated heparin.

Authors:  Colin K Yee; Martin Butcher; Melec Zeadin; Jeffrey I Weitz; Stephen G Shaughnessy
Journal:  Clin Exp Metastasis       Date:  2008-09-24       Impact factor: 5.150

9.  Antiangiogenic activity of orally absorbable heparin derivative in different types of cancer cells.

Authors:  Dong Yun Lee; Sung Won Lee; Sang Kyoon Kim; Myungjin Lee; Hyo Won Chang; Hyun Tae Moon; Youngro Byun; Sang Yoon Kim
Journal:  Pharm Res       Date:  2009-10-15       Impact factor: 4.200

10.  The antineoplastic effect of low-molecular-weight heparins - a literature review.

Authors:  Justyna Bochenek; Mirosława Püsküllüoğlu; Krzysztof Krzemieniecki
Journal:  Contemp Oncol (Pozn)       Date:  2013-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.